Tocilizumab in addition to standard of care in the management of COVID-19: a meta-analysis of RCTs.

ABSTRACT:

Objective

We performed a systematic review and meta-analysis for exploring clinical benefits and safety of tocilizumab in addition to standard of care (SOC) in treating patients with coronavirus disease 2019 (COVID-19).

Methods

An electronic search was carried out in PubMed, EMBASE, Cochrane Library, and Science Direct, as well as in medRxiv preprint server, to identify eligible studies. Only randomized Controlled Trials (RCTs) that compared mortality events and/or adverse events between a tocilizumab + SOC group and a SOC-only control group were included. The primary outcome was 28-day mortality. Secondary outcomes include progression to severe disease, defined as need for mechanical ventilation (MV) or intensive care unit (ICU) admission, and adverse events (AE).

Result

SUBMITTER: Mutua V 

PROVIDER: S-EPMC8972884 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature